SEARCH

SEARCH BY CITATION

References

  • 1
    Feldman EC, Nelson RW. Canine and Feline Endocrinology and Reproduction, 2nd ed. Philadelphia, PA: WB Saunders; 1995: 187265.
  • 2
    Schechter RD, Stabenfeldt GH, Gribble DH, Ling GV. Treatment of Cushing's syndrome in the dog with an adrenocorticolytic agent (o,p9-DDD). J Am Vet Med Assoc 1973; 162: 629639.
  • 3
    Rijnberk A., Belshaw BE. An alternative protocol for the medical management of canine pituitary-dependent hyperadrenocorticism. Vet Rec 1988; 122: 486488.
  • 4
    Kintzer PP, Peterson ME. Mitotane (o,p9-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticocism. J Vet Intern Med 1991; 5: 182190.
  • 5
    Peterson ME. Pathophysiology of canine pituitary-dependent hyperadrenocorticism (canine Cushing's disease). Front Horm Res 1987; 17: 3747.
  • 6
    Rijnberk A., Mol JA, Kwant MM, Croughs RJM. Effects of bromocriptine on corticotrophin, melanotrophin, and corticosteroid secretion in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1988; 118: 271277.
  • 7
    Peterson ME, Drucker WD. Cyproheptadine treatment of spontaneous pituitary ACTH-dependent canine Cushing's disease. Clin Res 1978; 26: 703A.
  • 8
    Stolp R., Croughs RJM, Rijnberk A. Results of cyproheptadine treatment in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1984; 101: 311314.
  • 9
    Feldman EC, Bruyette DS, Nelson RW, Farver TB. Plasma cortisol response to ketokonazole administration in dogs with hyperadrenocorticism. J Am Vet Med Assoc 1990; 197: 7178.
  • 10
    Bruyette DS, Ruehl WW, Smidberg TL. L-Deprenyl therapy of canine pituitary-dependent hyperadrenocorticism. 11th Annual Medical Forum ACVIM, Washington, DC, May, 1993:927.
  • 11
    Bruyette DS, Ruehl WW, Muggenburg B. Effects of chronic treatment with the monoamine oxidase inhibitor (L-Deprenyl) on CRH stimulation testing in geriatric beagle dogs. 12th Annual Medical Forum ACVIM, San Francisco, CA, June, 1994: 994.
  • 12
    Bruyette DS, Darling LA, Griffin D., Ruehl WW. L-Deprenyl for canine pituitary-dependent hyperadrenocorticism: Pivotal efficacy trial. 14th Annual Medical Forum ACVIM, San Antonio, TX, May, 1996: 764.
  • 13
    Bruyette DS, Ruehl WW, Entriken T., et al. Management of canine pituitary-dependent hyperadrenocorticism with L-Deprenyl (Anipryl).Vet Clin North Am Small Anim Pract 1997; 27 (2):273286.
  • 14
    Feldman EC. Distinguishing dogs with functioning adrenocortical tumors from dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1983; 183: 195200.
  • 15
    Haehnle B. Der Kortikotropin-Releasing-Hormon-Stimulationstest in der Untersuchung der Hypothalamus–Hypophysen–Nebennierenrindenachse bei Klinisch Gesunden Hunden und Hunden mit Cushing-Syndrom. Munich , Germany : University of Munich; 1992. Doctoral thesis.
  • 16
    Barthez PY, Nyland TG, Feldman EC. Ultrasonographic evaluation of the adrenal glands in dogs. J Am Vet Med Assoc 1995; 207: 11801183.
  • 17
    Hoerauf A., Reusch C. Darstellung der Nebennieren mittels Ultraschall: Untersuchungen bei gesunden Hunden, Hunden mit nichtendokrinen Erkrankungen sowie mit Cushing-Syndrom. Kleintierpraxis 1995; 40: 351360.
  • 18
    Feldman BF, Feldman EC. Routine laboratory diagnosis in endocrine disease. Vet Clin North Am 1977; 7: 443464.
  • 19
    Mol J., Slob A., Middleton DJ, Rijnberk A. Release of adrenocorticotropin and b-endorphin by pituitary tumors of dogs with pituitary-dependent hyperadrenocorticism. Front Horm Res 1987; 17: 6170.
  • 20
    Feldman EC, Nelson RW, Feldman MS. Use of low and highdose dexamethasone tests for distinguishing pituitary-dependent from adrenal tumor hyperadrenocorticism in dogs. J Am Vet Med Assoc 1996; 209: 772775.
  • 21
    Feldman EC. Comparison of ACTH response and dexamethasone suppression as screening tests in canince hyperadrenocorticism. J Am Vet Med Assoc 1983a;182:506510.
  • 22
    Soffner C., Reusch C. Untersuchungen zur Aussagekraft des Kortisol–Kreatinin-Verhältnisses im Urin (UC/C) für die Diagnose des caninen Hyperadrenocortizismus. Kleintierprax 1996; 41: 77152.
  • 23
    Reusch C., Feldman EC. Canine hyperadrenocorticism due to adrenocortical neoplasia. Pretreatment evaluation of 41 dogs. J Vet Intern Med 1991; 5: 310.
  • 24
    Peterson ME. Hyperadrenocorticism. Vet Clin North Am Small Anim Practice 1984; 14: 731749.
  • 25
    Ling GV, Stabenfeldt GH, Comer KM, et al. Canine hyperadrenocorticism: Pretreatment clinical and laboratory evaluation of 117 cases. J Am Vet Med Assoc 1979; 174: 12111215.
  • 26
    Scott DW. Hyperadrenocorticism (hyperadrenocorticoidism, hyperadrenocorticalism, Cushing's disease, Cushing's syndrome). Vet Clin North Am Small Anim Practice 1979; 9: 328.
  • 27
    Reusch C., Haehnle B. Labordiagnostische Parameter zur Therapieverlaufskontrolle des caninen Cushing-Syndroms. Tierarztl Prax 1991; 19: 102106.
  • 28
    Feldman EC, Nelson RW, Feldman MS, et al. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1992; 200: 16421647.
  • 29
    Dunn KJ, Herrtage MR, Dunn JK. Use of ACTH stimulation tests to monitor the treatment of canine hyperadrenocorticism. Vet Rec 1995; 137: 161165.
  • 30
    Reusch CE, Ruppert CB, Soffner T. Monitoring of individual response to o,p9-DDD (Lysodrent) during initial therapy in dogs with pituitary dependent hyperadrenocorticism. 13th Annual Medical Forum ACVIM, Lake Buena Vista, FL, May, 1995: 1001.
  • 31
    Angels JM, Feldman EC, Nelson RW, Feldman MS. Use of urine cortisol: Creatinine ratio versus adrenocorticotropic hormone stimulation testing for monitoring mitotane treatment of pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1997; 211: 10021004.
  • 32
    Hoerauf A., Steffen T., Reusch C. Auswirkungen der CushingTherapie mittels o,p9-DDD und Selegelin-Hydrochlorid auf die Nebennierengrösse:—Eine sonographische Studie. 6. Jahrestagung der Fachgruppe Innere Medizin und Labordiagnostik der DVG, München, Germany, March 5–9, 1997.
  • 33
    Hoerauf A., Reusch C. Ultrasonographic characteristics of both adrenal glands in 15 dogs with functional adrenocortical tumors. J Am Anim Hosp Assoc 1998, in press.
  • 34
    Kemppainen RJ, Sartin JL. In vivo evidence for dopaminergic regulation of the canine pituitary intermediate lobe. Acta Endocrinol 1986; 113: 471478.
  • 35
    Peterson ME, Orth DN, Halmi NS, et al. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Addison's disease and Cushing's syndrome: Basal concentrations. Endocrinology 1986; 119: 720730.
  • 36
    Zerbe CA, Clark TP, Sartin JL, Kemppainen RJ. Domperidone treatment enhances corticotropin-releasing hormone stimulated adrenocorticotropic hormone release from the dog pituitary. Neuroendocrinology 1993; 57: 282288.
  • 37
    Biller AMK, Alexander JM, Zervas NT, et al. Clonal origins of adrenocrticotropin-secreting pituitary tissue in Cushing's disease. J Clin Endocrinol Metab 1992; 75: 13031309.
  • 38
    Gicquel C., Bouc YL, Luton JP, et al. Monoclonality of corticotroph macroadenomas in Cushing's disease. J Clin Endocrinol Metab 1992; 75: 472475.
  • 39
    Avgerinos PC, Nieman LK, Oldfield EH, et al. The effect of pulsatile human corticotropin-releasing hormone administration on the adrenal insufficiency that follows cure of Cushing's disease. J Clin Endocrinol Metab 1989; 68: 912916.
  • 40
    Van Wijk PA, Rijnberk A., Croughs RJM, et al. Corticotropinreleasing hormone and adreno-corticotropic hormone concentrations in cerebrospinal fluid of dogs with pituitary-dependent hyperadrenocorticism. Endocrinology 1992; 131: 26592662.
  • 41
    Scholten-Sloof BE, Knol BW, Rijnberk A., et al. Pituitary-dependent hyperadrenocorticism in a family of Dandie Dinmont Terriers. J Endocrinol 1992; 135: 535542.
  • 42
    Bertoy EH, Feldman EC, Nelson RW, et al. Magnetic resonance imaging of the brain in dogs with recently diagnosed but untreated pituitary dependent hyperadrenocorticism. J Am Vet Med Assoc 1995; 206: 651656.
  • 43
    Bertoy EH, Feldman EC, Nelson RW, et al. One-year followup evaluation of magnetic resonance imaging of the brain in dogs with pituitary-dependent hyperadrenocorticism. J Am Vet Med Assoc 1996; 208: 12681273.
  • 44
    Kooistra HS, Voorhout G., Mol JA, Rijnberk A. Correlation between impairment of glucocorticoid feedback and the size of the pituitary gland in dogs with pituitary-dependent hyperadrenocorticism. J Endocrinol 1997; 152: 387394.
  • 45
    Rijnberk A., Mol JA, Rothuizen J., et al. Circulating pro-opiomelanocortin-derived peptides in dogs with pituitary-dependent hyperadrenocorticism. Front Horm Res 1987; 17: 4860.
  • 46
    Orth DN, Peterson ME, Drucker WD. Plasma immunoreactive proopiomelanocortin peptides and cortisol in normal dogs and dogs with Cushing's syndrome: Diurnal rhythm and responses to various stimuli. Endocrinology 1988; 122: 12501262.
  • 47
    Smals AGH, Pieters GFFM, Van Haelst UJG, Kloppenborg PW. Macronodular hyperplasia in long-standing Cushing's disease. J Endocrinol Metab 1984; 58: 2531.
  • 48
    Milgram NW, Ivy GO, Murphy MP, et al. Effects of chronic oral administration of L-Deprenyl in the dog. Pharmacol Biochem Behav 1995; 51(2/3):421428.